The global demand for Agoraphobia Treatment Market is presumed to reach the valuation of nearly USD XX MN by 2026 from USD XX MN in 2019 with a CAGR of XX% under the study period of 2020 - 2026.
The word agoraphobia is originated from the ancient Greek word “agora”, which means a place of assembly or a market place. Agoraphobia is an anxiety disorder, which involves fear of places, fear of the crowd, public transport, malls, elevators, etc. It further involves fear of going out of the house and fear of being outside alone. The agoraphobia situation causes a feeling of embarrassment, panic, helplessness, and a feeling of being trapped. Physical symptoms of agoraphobia are shortness of breath, dizziness, and chest pains. The treatment for agoraphobia includes anti-depressant drugs, anxiety-reducing medicine, Cognitive Behavioural Therapy (CBT), and psychotherapy.
The increasing prevalence of agoraphobia, especially in women is the key factor, which is driving the global agoraphobia treatment market. Besides a fear of places, agoraphobia is related to the other types of anxiety disorders, such as social phobia, fear of using substances, and other specific phobias. Rapidly growing global pandemic COVID-19 spreads through direct close contacts, or by touching the infected surfaces or objects, it may lead to an increase in agoraphobia and other associated psychological fears among individuals across the globe. The increase in fear and agoraphobia is anticipated to increase the demand for agoraphobia treatment and promote the global agoraphobia treatment market.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of agoraphobia treatment.
The entire agoraphobia treatment market has been sub-categorized into treatment and end-user. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
- Cognitive Behavioral Therapy
- Anti-Anxiety Medications
- Specialty Clinics
This section covers regional segmentation which accentuates on current and future demand for agoraphobia treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Agoraphobia Treatment Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the agoraphobia treatment market include Eli Lilly & Co., Glaxosmithkline plc, Pfizer Inc., AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Sandoz Inc., Apotex Corp., Mylan Pharmaceuticals Inc. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.